Dissociation of blood-brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7

Immunopharmacology

Volumn 33, Issue 1-3, 1996, Pages 205-208

  Elliott, P J ^a   Hayward, N J ^a   Dean, R L ^a   Bartus, R T ^a  

^a ALKERMES INC   (United States)

Author keywords

blood brain barrier permeability; bradykinin agonist; RMP 7; tumor

Indexed keywords

ADENOSINE 5' (N ETHYLCARBOXAMIDE); BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CARBOPLATIN; DEXTRAN; ICATIBANT; LOBRADIMIL; RADIOLIGAND;

ANIMAL EXPERIMENT; BLOOD BRAIN BARRIER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG UPTAKE; GLIOMA CELL; HYPOTENSION; INTERNAL CAROTID ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030175504     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00041-0     Document Type: Conference Paper

References (2)

1. Bartus, R.T., Elliott, P., Hayward, N., matsukado, K. and Black, K. Bradykinin permeation of the blood-brain barrier: Evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology, 33: 268-279.
2. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J. Neurosurg., 1994; 81: 752-758.